1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 21 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2007Proximal gastric motility in critically ill patients with type 2 diabetes mellitusNguyen, Q.; Fraser, R.; Bryant, L.; Chapman, M.; Holloway, R.
2007The impact of admission diagnosis on gastric emptying in critically ill patientsNguyen, Q.; Ng, M.; Chapman, M.; Fraser, R.; Holloway, R.
2006Fasting and nutrient-stimulated plasma peptide-YY levels are elevated in critical illness and associated with feed intolerance: an observational, controlled studyNguyen, Q.; Fraser, R.; Chapman, M.; Bryant, L.; Wishart, J.; Holloway, R.; Horowitz, M.
2008The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illnessNguyen, Q.; Chapman, M.; Fraser, R.; Bryant, L.; Burgstad, C.; Ching, K.; Bellon, M.; Holloway, R.
2005Transient lower esophageal sphincter relaxations (TLESRs) are the major mechanism of gastroesophageal reflux but are not the cause of reflux diseaseIwakiri, K.; Hayashi, Y.; Kotoyori, M.; Tanaka, Y.; Kawakami, A.; Sakamoto, C.; Holloway, R.
2007Prokinetic therapy with erythromycin has no significant impact on blood pressure and heart rate in critically ill patientsNguyen, Q.; Mangoni, A.; Fraser, R.; Chapman, M.; Bryant, L.; Burgstad, C.; Holloway, R.
2008The impact of delaying enteral feeding on gastric emptying plasma cholecystokinin and peptide YY concentrations in critically ill patientsNguyen, Q.; Fraser, R.; Bryant, L.; Burgstad, C.; Chapman, M.; Bellon, M.; Wishart, J.; Holloway, R.; Horowitz, M.
2007Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illnessNguyen, Q.; Chapman, M.; Fraser, R.; Bryant, L.; Holloway, R.
2007Prokinetic therapy for feed intolerance in critical illness: One drug or two?Nguyen, Q.; Chapman, M.; Fraser, R.; Bryant, L.; Burgstad, C.; Holloway, R.
2009Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostateYeoh, E.; Holloway, R.; Fraser, R.; Botten, R.; Di Matteo, A.; Moore, J.; Schoeman, M.; Bartholomeusz, F.

Discover